{
  "type": "hyp",
  "text": "The authors evaluated the effects of thalidomide on the proliferation of glioblastoma cells in vitro and in vivo. These parameters were not modified by Nef expression in control animals or by inhibition of cell proliferation in vitro.\n",
  "self": {
    "NER": {
      "answers": [
        "Nef"
      ],
      "QG_hash=ThomasNLG/t5-qg_squad1-en": {
        "questions": [
          "What gene was not altered in control animals?"
        ]
      }
    },
    "NOUN": {
      "answers": [
        "The authors",
        "the effects",
        "thalidomide",
        "the proliferation",
        "glioblastoma cells",
        "vitro",
        "vivo",
        "These parameters",
        "Nef expression",
        "control animals",
        "inhibition",
        "cell proliferation"
      ],
      "QG_hash=ThomasNLG/t5-qg_squad1-en": {
        "questions": [
          "Who evaluated the effects of thalidomide on the proliferation of glioblasto",
          "What did the authors evaluate on the proliferation of glioblastoma cells?",
          "What drug was used to treat glioblastoma?",
          "What did the authors evaluate the effects of thalidomide on?",
          "What did the authors evaluate the effects of thalidomide on?",
          "In what way did the authors evaluate the effects of thalidomide on glio",
          "In what way did the authors evaluate the effects of thalidomide on glio",
          "What did the authors evaluate in vitro and in vivo?",
          "What did the authors not modify in control animals?",
          "What animals were not affected by the effects of thalidomide?",
          "What was not modified by Nef expression in control animals?",
          "What did the authors evaluate the effects of thalidomide on?"
        ]
      }
    }
  },
  "asked": {
    "What is the prognostic factor for gliomas?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.0033847689628601074,
        "ground_truth": {
          "CTGF": {
            "bertscore": 0.6617788672447205,
            "f1": 0
          },
          "CYR61": {
            "bertscore": 0.5884224772453308,
            "f1": 0
          },
          "tumor progression": {
            "bertscore": 0.6921792030334473,
            "f1": 0
          },
          "survival": {
            "bertscore": 0.6987523436546326,
            "f1": 0
          },
          "individuals": {
            "bertscore": 0.7371072769165039,
            "f1": 0
          }
        }
      }
    },
    "What is prognostic for tumor progression and survival?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.002621293067932129,
        "ground_truth": {
          "Levels": {
            "bertscore": 0.7182135581970215,
            "f1": 0
          }
        }
      }
    },
    "What is a prognostic factor for gliomas?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.05143803358078003,
        "ground_truth": {
          "expression": {
            "bertscore": 0.7272055745124817,
            "f1": 0
          }
        }
      }
    },
    "What is the prognostic factor for tumor progression?": {
      "QA_hash=ThomasNLG/t5-qa_squad2neg-en": {
        "answer": "unanswerable",
        "answerability": 0.0030887722969055176,
        "ground_truth": {
          "gliomas": {
            "bertscore": 0.646902322769165,
            "f1": 0
          }
        }
      }
    }
  }
}